Purpose of this Study
This study has two parts. In the first part, called Phase 1a, doctors will test different amounts of a medicine called PHN-012 to find the safest dose. In the second part, called Phase 1b, doctors will see how well PHN-012 works against cancer. The medicine will be given through an IV, which means it goes into a vein. You will get the medicine every 21 days until your cancer gets worse or you have to stop because of bad side effects.
Who Can Participate?
Eligibility
To join this study, you must be 18 years or older and have already had at least one treatment for advanced disease. You can join if there are no other proven treatments left, if you cannot handle the side effects of standard treatments, or if you choose not to have standard treatment after learning about all your options.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
The study wants to find out if a medicine called PHN-012 is safe and if people can handle it well. It also wants to see how well PHN-012 works to fight advanced solid tumors, which are a type of cancer.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors
Principal Investigator
John
Strickler
Protocol Number
PRO00119232
NCT ID
NCT07127874
Phase
I
Enrollment Status
Pending Open to Enrollment